Disease severity scoring systems in mucosal lichen planus: A systematic review
- PMID: 36404123
- DOI: 10.1111/odi.14447
Disease severity scoring systems in mucosal lichen planus: A systematic review
Abstract
Several scoring systems have been developed to evaluate disease severity in mucosal lichen planus, but only a few have been validated to ensure reproducible and accurate assessment of disease severity. The current systematic review was undertaken to identify clinical severity scoring systems in mucosal lichen planus that have undergone validity or reliability testing and to describe their operating characteristics. We performed a bibliographic search in five databases from their inception to October 2022 for severity scoring systems in mucosal lichen planus that have undergone validity or reliability tests. Quality assessment was conducted using the Joanna Briggs Institute Critical Appraisal tools. We have included 118 studies and identified 11 clinical severity scoring systems for oral lichen planus that have undergone validity or reliability testing. Of these, the most reported were the Thongprasom score, the Oral Disease Severity Score (ODSS) and the REU (Reticular/hyperkeratotic, Erosive/erythematous, Ulcerative) scoring systems. We did not identify clinical scoring systems for extraoral mucosal lichen planus that have undergone validity or reliability testing. The ODSS and REU scoring systems have undergone the highest number of validation attempts and reliability assessments for oral lichen planus respectively. However, we have identified numerous factors that have hampered the universal adoption of a standardised scoring system. There is a need for the development and validation of scoring systems for extraoral mucosal lichen planus.
Keywords: clinical scoring systems; mucosal lichen planus; oral lichen planus; reliability; validity.
© 2022 The Authors. Oral Diseases published by Wiley Periodicals LLC.
Similar articles
-
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD011450. doi: 10.1002/14651858.CD011450.pub2. Cochrane Database Syst Rev. 2018. PMID: 29338066 Free PMC article.
-
Clinical predictors of disease severity in oral lichen planus.Clin Exp Dermatol. 2025 May 23;50(6):1146-1154. doi: 10.1093/ced/llae558. Clin Exp Dermatol. 2025. PMID: 39750743
-
The measurement and monitoring of surgical adverse events.Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220. Health Technol Assess. 2001. PMID: 11532239
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
Cited by
-
Escherichia coli aggravates inflammatory response in mice oral mucositis through regulating Th17/Treg imbalance.Front Cell Infect Microbiol. 2025 Apr 29;15:1585020. doi: 10.3389/fcimb.2025.1585020. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40365536 Free PMC article.
-
Development and validation of the Oral Lichen Planus-Disease Activity Scale: a novel tool for comprehensive clinical assessment.Clin Oral Investig. 2024 Aug 12;28(9):481. doi: 10.1007/s00784-024-05875-0. Clin Oral Investig. 2024. PMID: 39129032
-
Desmoglein-3 autoantibodies in tissues of oral lichen planus patients and its correlation with disease severity: case-control study.BMC Oral Health. 2025 Jun 6;25(1):930. doi: 10.1186/s12903-025-06303-9. BMC Oral Health. 2025. PMID: 40481453 Free PMC article.
-
Supplementary zinc and vitamin D in management of symptomatic oral lichen planus: a three-arm randomized clinical trial.BMC Oral Health. 2025 Jun 2;25(1):872. doi: 10.1186/s12903-025-06173-1. BMC Oral Health. 2025. PMID: 40457259 Free PMC article. Clinical Trial.
-
Association between Epstein Barr virus and Oral Lichen Planus clinical phenotypes and p53 expression.Sci Rep. 2025 Jul 24;15(1):26977. doi: 10.1038/s41598-025-12095-3. Sci Rep. 2025. PMID: 40707534 Free PMC article.
References
REFERENCES
-
- Agha-Hosseini, F., Borhan-Mojabi, K., Monsef-Esfahani, H. R., Mirzaii-Dizgah, I., Etemad-Moghadam, S., & Karagah, A. (2010). Efficacy of purslane in the treatment of oral lichen planus. Phytotherapy Research, 24(2), 240-244. https://doi.org/10.1002/ptr.2919
-
- Andreasen, J. 0, & Copenhagen, D. D. S. (1968). Oral lichen planus I. a clinical evaluation of 115 cases. Oral Surgery, Oral Medicine and Oral Pathology, 31-42, 25.
-
- Aromataris, E., & Munn, Z. (Eds.). (2020). JBI manual for evidence synthesis. JBI. https://doi.org/10.46658/JBIMES-20-01
-
- Chainani-Wu, N., Silverman, S., Reingold, A., Bostrom, A., Lozada-Nur, F., & Weintraub, J. (2008). Validation of instruments to measure the symptoms and signs of oral lichen planus. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 105(1), 51-58. https://doi.org/10.1016/j.tripleo.2007.06.022
-
- Chainani-Wu, N., Silverman, S., Reingold, A., Bostrom, A., Mc Culloch, C., Lozada-Nur, F., & Weintraub, J. (2007). A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine, 14(7-8), 437-446. https://doi.org/10.1016/j.phymed.2007.05.003
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources